Imaging Flow Cytometric Assessment of del(17p) and amp(1q21) in Circulating Plasma Cells of Myeloma Patients
Current Protocols · 2026
DOI: 10.1002/cpz1.70305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Protocols, 2026. Verfasst von Thomas I Mincherton und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, The University of Western Australia, Crawley, Australia. Hauptthemen laut MEDLINE: Multiple Myeloma, Flow Cytometry, Plasma Cells, Chromosomes, Human, Pair 1. Die Arbeit nennt 17 Literaturangaben. Gefördert von: National Health and Medical Research Foundation, Australian Government Research Training Program scholarship, Leukaemia Foundation Australia.
Abstract (Originalsprache)
Multiple myeloma is a bone marrow–derived neoplastic proliferation of plasma cells with low levels of circulating tumor cells. Cytogenetic abnormalities are present in >90% of patients, when assessed by fluorescence in situ hybridization (FISH) on bone marrow, and the specific abnormalities provide vital prognostic information. Provided is a protocol for assessing the high‐risk abnormalities del(17p) and amp(1q21) in the circulating plasma cells of myeloma patients by flow cytometry. This utilizes positive plasma cell identification by standard immunophenotyping and then chromosomal analysis by FISH using an imaging flow cytometer. Integrating cell phenotype and FISH in one test, a method called “immuno‐flowFISH” allows for the detection of cytogenetic abnormalities in plasma cells identified by their antigenic profile. This method can be applied to both bone marrow and blood samples to detect primary abnormalities [i.e., hyperdiploidy; immunoglobulin heavy locus ( IGH ) translocation] and secondary abnormalities [i.e., del(17p) found in 10% of patients, and gain(1q) present in ∼40% of patients with myeloma]. Here we describe the protocol for the simultaneous detection of these secondary abnormalities in blood and bone marrow samples from myeloma patients that enables detection of single or “double hit” abnormalities, with the latter classified as ultra high–risk disease. The protocol includes the data analysis strategy, as well as the statistics used to confirm the presence of these abnormalities. Applying this method will facilitate blood‐based monitoring for the presence and evolution of these critical cytogenetic abnormalities. © 2026 Wiley Periodicals LLC. Basic Protocol : Immuno‐flowFISH assessment of del(17p) and amp(1q21) in multiple myeloma Support Protocol : Validation of single fluorophore for positive markers in multiple myeloma
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Sciences, The University of Western Australia, Crawley, Australia.
- Medical School, The University of Western Australia, Crawley, Australia.
- Haematology Department, Fiona Stanley Hospital, Murdoch, Australia.
- PathWest Laboratory Medicine, Nedlands, Australia.
ORCID-Profile: Kathy A Fuller
Förderung
- National Health and Medical Research Foundation
- Australian Government Research Training Program scholarship
- Leukaemia Foundation Australia
Zitieren
APA
Mincherton, T. I., Harms, M., Clarke, S. E., Hui, H. Y. L., Erber, W. N., & Fuller, K. A. (2026). Imaging Flow Cytometric Assessment of del(17p) and amp(1q21) in Circulating Plasma Cells of Myeloma Patients. Current Protocols. https://doi.org/10.1002/cpz1.70305
Vancouver
Mincherton TI, Harms M, Clarke SE, Hui HYL, Erber WN, Fuller KA. Imaging Flow Cytometric Assessment of del(17p) and amp(1q21) in Circulating Plasma Cells of Myeloma Patients. Current Protocols. 2026. doi:10.1002/cpz1.70305
BibTeX
@article{Mincherton2026,
author = {Mincherton, Thomas I and Harms, Matthew and Clarke, Sarah E and Hui, Henry Y L and Erber, Wendy N and Fuller, Kathy A},
title = {Imaging Flow Cytometric Assessment of del(17p) and amp(1q21) in Circulating Plasma Cells of Myeloma Patients},
journal = {Current Protocols},
year = {2026},
doi = {10.1002/cpz1.70305}
}
EUVIMED